{"id":48867,"date":"2025-11-24T21:03:35","date_gmt":"2025-11-24T13:03:35","guid":{"rendered":"https:\/\/flcube.com\/?p=48867"},"modified":"2025-11-24T21:03:36","modified_gmt":"2025-11-24T13:03:36","slug":"luyes-ly03017-wins-fda-nod-for-psychosis-trials-in-alzheimers-and-parkinsons","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48867","title":{"rendered":"Luye&#8217;s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer&#8217;s and Parkinson&#8217;s"},"content":{"rendered":"\n<p><strong>Luye Pharma Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2186:HKG\">HKG: 2186<\/a>) announced that its independently developed <strong>LY03017<\/strong> received <strong>U.S. FDA permission<\/strong> to conduct clinical trials for <strong>Alzheimer&#8217;s disease psychosis (ADP), Parkinson&#8217;s disease psychosis (PDP), and negative symptoms of schizophrenia (NSS)<\/strong>. The drug is a next\u2011generation <strong>5\u2011HT2A receptor inverse agonist and 5\u2011HT2C receptor antagonist<\/strong> also in <strong>Phase\u202fI trials in China<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>LY03017<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Luye Pharma Group (2186.HK)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial permission<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>ADP, PDP, NSS<\/td><\/tr><tr><td><strong>China Status<\/strong><\/td><td>Phase\u202fI clinical trials ongoing<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>New Molecular Entity\/New Therapeutic Entity (NME\/NTE)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Dual action as <strong>5\u2011HT2A receptor inverse agonist<\/strong> and <strong>5\u2011HT2C receptor antagonist<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Reduces hallucinations\/delusions in ADP\/PDP and improves NSS by modulating dopamine release<\/li>\n\n\n\n<li>Inhibits dopamine release in ventral striatum<\/li>\n\n\n\n<li>Promotes dopamine release in prefrontal cortex<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Next\u2011generation CNS therapeutic with <strong>superior pharmacological activity, tissue distribution, and cardiac safety<\/strong> vs. marketed and investigational competitors (per preclinical data)<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> Concurrent development in <strong>China and U.S.<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-plan\">Clinical Development Plan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase\u202fI (U.S. and China)<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Safety, tolerability, PK\/PD, initial efficacy signals<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>ADP, PDP, NSS patients<\/td><\/tr><tr><td><strong>Endpoints<\/strong><\/td><td>PANSS scores, CGI\u2011I, cardiac safety (QTc)<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Dosing of first U.S. patient expected Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China PDP\/ADP Patients<\/strong><\/td><td>~<strong>1.5\u202fmillion<\/strong> (combined)<\/td><\/tr><tr><td><strong>NSS Patients (China)<\/strong><\/td><td>~<strong>2.8\u202fmillion<\/strong> schizophrenia patients, ~30% with prominent negative symptoms<\/td><\/tr><tr><td><strong>CNS Psychosis Market Size<\/strong><\/td><td>\u00a512\u202fbillion (US$1.6\u202fbillion)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>9% (2024\u20112030)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (LY03017)<\/strong><\/td><td><strong>\u00a53.5\u20114.5\u202fbillion<\/strong> (US$480\u2011610\u202fmillion) by 2033<\/td><\/tr><tr><td><strong>Competitive Landscape:<\/strong><\/td><td><strong>Acadia\u2019s Nuplazid<\/strong> (approved for PDP only); no approved therapies for ADP or NSS in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation:<\/strong> Dual 5\u2011HT2A\/C mechanism offers broader efficacy vs. single\u2011target agents; superior cardiac safety addresses key Nuplazid liability (QT prolongation)<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Positions Luye as <strong>first\u2011mover<\/strong> in ADP\/NSS segments; Phase\u202fI data could trigger <strong>Breakthrough Therapy Designation<\/strong> in U.S.<\/li>\n\n\n\n<li><strong>Next Catalyst:<\/strong> Interim Phase\u202fI safety data <strong>Q4\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding LY03017\u2019s clinical development, regulatory pathway, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics in the CNS therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112400022_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025112400022_c.\"><\/object><a id=\"wp-block-file--media-7cd31702-c127-4ed0-9882-883dc18af764\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112400022_c.pdf\">2025112400022_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112400022_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7cd31702-c127-4ed0-9882-883dc18af764\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48871,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1023,219],"class_list":["post-48867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-2186","tag-luye-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luye&#039;s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer&#039;s and Parkinson&#039;s - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA permission to conduct clinical trials for Alzheimer&#039;s disease psychosis (ADP), Parkinson&#039;s disease psychosis (PDP), and negative symptoms of schizophrenia (NSS). The drug is a next\u2011generation 5\u2011HT2A receptor inverse agonist and 5\u2011HT2C receptor antagonist also in Phase\u202fI trials in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48867\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye&#039;s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer&#039;s and Parkinson&#039;s\" \/>\n<meta property=\"og:description\" content=\"Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA permission to conduct clinical trials for Alzheimer&#039;s disease psychosis (ADP), Parkinson&#039;s disease psychosis (PDP), and negative symptoms of schizophrenia (NSS). The drug is a next\u2011generation 5\u2011HT2A receptor inverse agonist and 5\u2011HT2C receptor antagonist also in Phase\u202fI trials in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48867\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T13:03:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T13:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye&#8217;s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer&#8217;s and Parkinson&#8217;s\",\"datePublished\":\"2025-11-24T13:03:35+00:00\",\"dateModified\":\"2025-11-24T13:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2404.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 2186\",\"Luye Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48867#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48867\",\"name\":\"Luye's LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer's and Parkinson's - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2404.webp\",\"datePublished\":\"2025-11-24T13:03:35+00:00\",\"dateModified\":\"2025-11-24T13:03:36+00:00\",\"description\":\"Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA permission to conduct clinical trials for Alzheimer's disease psychosis (ADP), Parkinson's disease psychosis (PDP), and negative symptoms of schizophrenia (NSS). The drug is a next\u2011generation 5\u2011HT2A receptor inverse agonist and 5\u2011HT2C receptor antagonist also in Phase\u202fI trials in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48867\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2404.webp\",\"width\":1080,\"height\":608,\"caption\":\"Luye's LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer's and Parkinson's\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48867#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye&#8217;s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer&#8217;s and Parkinson&#8217;s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye's LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer's and Parkinson's - Insight, China&#039;s Pharmaceutical Industry","description":"Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA permission to conduct clinical trials for Alzheimer's disease psychosis (ADP), Parkinson's disease psychosis (PDP), and negative symptoms of schizophrenia (NSS). The drug is a next\u2011generation 5\u2011HT2A receptor inverse agonist and 5\u2011HT2C receptor antagonist also in Phase\u202fI trials in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48867","og_locale":"en_US","og_type":"article","og_title":"Luye's LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer's and Parkinson's","og_description":"Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA permission to conduct clinical trials for Alzheimer's disease psychosis (ADP), Parkinson's disease psychosis (PDP), and negative symptoms of schizophrenia (NSS). The drug is a next\u2011generation 5\u2011HT2A receptor inverse agonist and 5\u2011HT2C receptor antagonist also in Phase\u202fI trials in China.","og_url":"https:\/\/flcube.com\/?p=48867","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-24T13:03:35+00:00","article_modified_time":"2025-11-24T13:03:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48867#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48867"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye&#8217;s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer&#8217;s and Parkinson&#8217;s","datePublished":"2025-11-24T13:03:35+00:00","dateModified":"2025-11-24T13:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48867"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48867#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2404.webp","keywords":["Clinical trial approval \/ initiation","HKG: 2186","Luye Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48867#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48867","url":"https:\/\/flcube.com\/?p=48867","name":"Luye's LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer's and Parkinson's - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48867#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48867#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2404.webp","datePublished":"2025-11-24T13:03:35+00:00","dateModified":"2025-11-24T13:03:36+00:00","description":"Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA permission to conduct clinical trials for Alzheimer's disease psychosis (ADP), Parkinson's disease psychosis (PDP), and negative symptoms of schizophrenia (NSS). The drug is a next\u2011generation 5\u2011HT2A receptor inverse agonist and 5\u2011HT2C receptor antagonist also in Phase\u202fI trials in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48867#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48867"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48867#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2404.webp","width":1080,"height":608,"caption":"Luye's LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer's and Parkinson's"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48867#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye&#8217;s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer&#8217;s and Parkinson&#8217;s"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48867"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48867\/revisions"}],"predecessor-version":[{"id":48872,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48867\/revisions\/48872"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48871"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}